ClinicalTrials.gg
CompletedNCT03874494Updated Apr 18, 2025

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

A Phase 3 interventional study of Brexpiprazole and Aripiprazole in Schizophrenia, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
8th of 28
371 · median 155
Started
2019
the only one that year
Phase 3
16 of 28
none open now
Registered
26th of 28
by date
Lead sponsor
1 of 28
Otsuka Beijing Research Institute

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 16 in phase 3, and was the 26th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study is a phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial designed to assess the efficacy and safety of Brexpiprazole in the Treatment of Adults With Acute Schizophrenia. A total of approximately 370 subjects will be included in the study, and randomized to Brexpiprazole (2\~4 mg/d) or Aripiprazole (10\~20 mg/d) in a 1:1 ratio.

Read the detailed description

Screening Phase: It will begin when informed consent form (ICF) is signed and be a maximum of 14 days, to evaluate the inclusion/exclusion criteria, collect information such as demographic data, medical history, wash out previous antipsychotic agents and other prohibited concomitant medications.

Double-blind Treatment Phase: It lasts 6 weeks; the purpose is to compare the efficacy and safety of Brexpiprazole with Aripiprazole in the treatment of adults with acute schizophrenia.

Follow-up Phase: All subjects will be followed up for safety reasons via telephone contact or clinic visit 30 (+ 2) days after the last dose of investigational medicinal product, collecting safety information (adverse events and concomitant medication).

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Brexpiprazole
  • Non-inferiority
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written form by subjects and subject's legal guardian or legally acceptable representative.
  2. The subjects and subject's legal guardian or legally acceptable representative have the ability to understand the nature of the trial, agree to comply with the prescribed medication and dosage regimens, complete the scheduled visits, report the adverse events and concomitant medication to investigators, and to be reliably rated on psychiatrically scales.
  3. At the time of signing informed consent, 18 ≤ age of the subject ≤ 65.
  4. Subjects who are diagnosed with schizophrenia according to , Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by Mini International Neuropsychiatric Interview (MINI).
  5. Subjects who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the screening and baseline visit:

    ● PANSS total score ≥ 70;

    • Score ≥ 4 on at least 2 of the following PANSS items :

    ( P2 Conceptual disorganization, P3 Hallucinatory behavior, P6 Suspiciousness / persecution, G9 Unusual thought content ) ● CGI-S score ≥ 4;

  6. Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.

Exclusion criteria

Exclusion Criteria:

  1. From ICF to 30 days after the last dose, females of and male subjects who are not willing or cannot practice methods.
  2. Females who are pregnant or breastfeeding.
  3. Subjects who have been hospitalized for > 21 days for the current acute episode at the time of the Baseline visit, excluding hospitalization for psychosocial reasons.
  4. Subjects with improvement of ≥ 30% in total PANSS score between the screening and baseline assessment. Improvement in PANSS score= (score at screening-score at baseline)/ (score at screening-30)*100%.
  5. Subjects with schizophrenia who are considered resistant/ to antipsychotic treatment by history of failure to respond to 2 adequate different antipsychotic medications with a minimum of 6 weeks at clinically efficacious tolerated doses. Subjects who have a systemic treatment of clozapine.
  6. Subjects with a current Axis I diagnosis (including but not limited to): schizoaffective disorder, MDD, bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic or other cognitive disorders.
  7. Subjects with a current DSM-IV-TR Axis II diagnosis: borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorders.
  8. Subjects who present a serious risk of suicide:

    ● Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4 or 5 and meeting the criteria for this C-SSRS Item 4 or 5 occurred within the last 6 months; OR

    ● Subjects who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items and meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years; OR

    ● Subjects who, in the opinion of the investigator, present a serious risk of suicide

  9. Subjects with clinically diagnosed tardive dyskinesia, as determined by a score of ≥ 3 in Item 8 of the AIMS at the Screening visit.
  10. Subjects with a score of 5 in the BARS global clinical assessment of akathisia at Screening or Baseline.
  11. Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the 180 days prior to Screening Visit; including alcohol and benzodiazepines, but excluding caffeine and nicotine.
  12. Subjects with uncontrolled thyroid disease and/or abnormal free thyroxine (FT4) examination results at Screening, unless it has been confirmed by the investigator that the condition has been stabilized by medication > 90 days before screening
  13. Subjects with type I diabetes or uncontrolled type II diabetes. Subjects with type II diabetes may be eligible for the trial if their condition is stable as determined by satisfying ALL of the following criteria:

    • \< 7.0%, AND
    • Glucose must be ≤ 125 mg/dL or ≤ 6.94 mmol/L (fasting) or \< 200 mg/dL or \< 11.1 mmol/L (non-fasting) at Screening. If the non-fasting glucose is ≥ 200 mg/dL or ≥ 11.1 mmol/L, subjects must be retested in a fasted state and the retest value must be ≤ 125 mg/dL or ≤ 6.94 mmol/L, AND
    • Subjects have maintained a stable regimen of oral anti-diabetic medication(s) for at least 28 days prior to screening or diabetes has been well-controlled by diet for at least 28 days prior to screening, AND
    • Subjects have not had any hospitalizations within the 12 months prior to screening due to diabetes or complications related to diabetes, AND
    • Subjects whose diabetes is not newly diagnosed during screening for the trial.
  14. Subjects with uncontrolled hypertension (diastolic blood pressure > 95 mmHg in any position) or symptomatic hypotension, or orthostatic hypotension which is defined as a decrease of ≥ 30 mmHg in systolic blood pressure and/or a decrease of ≥ 20 mmHg in diastolic blood pressure after at least 3 minutes standing compared to the previous supine blood pressure, OR development of symptoms.
  15. Subjects with a history of ischemic heart disease or history of myocardial infarction, congestive heart failure (whether controlled or uncontrolled), angioplasty, stenting, or coronary artery bypass surgery.
  16. Subjects who have a history or severe organic disease of vital organs (including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease).
  17. Subjects with epilepsy or a history of seizures, except for a single seizure episode, for instance childhood febrile seizure and post traumatic or alcohol withdrawal.
  18. The following laboratory test and results are exclusionary:
  1. ≤ 75,000/mm3 (≤ 75 x 109 /L) 2) ≤ 9 g/dL (90 g/L) 3) Neutrophils ≤ 1,000/mm3 (1 x 109 /L) 4) or ALT > 2 × 5) CPK > 3 × ULN 6) Creatinine ≥ 2 mg/dL (176.8 µmol/L) 7) HbA1c ≥ 7.0% 8) ≥ 450 msec (for males) or ≥ 470 msec (for females) in ECG 19. Subjects who received ECT within 60 days of screening. 20. Subjects with a history of neuroleptic malignant syndrome (NMS). 21. Subjects with a history of true allergic response (ie, not intolerance) to more than one class of medications.
  1. Subjects who participated in a clinical trial within the last 90 days or who participated in two or more clinical trials within the past year.
  1. Any subject who, in the opinion of the investigator, should not participate in the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    2-4 mg/day, once daily for 6 weeks, oral administration

    Drug: Brexpiprazole

  • Active comparator
    Aripiprazole

    10-20 mg/day, once daily for 6 weeks, oral administration

    Drug: Aripiprazole

Interventions

  • Brexpiprazole 2-4 mg/day

    Also known as: Brexpiprazole Tablets

  • Aripiprazole 10-20 mg/day

    Also known as: Aripiprazole Tablets

06

What researchers measure

Primary outcomes

  1. Positive and Negative Syndrome Scale (PANSS) total score

    The Positive and Negative Syndrome Scale (PANSS) measures psychotic symptoms in patients with schizophrenia. PANSS includes 30 items (7 items for positive symptoms, 7 items for negative symptoms, and 16 items for general psychopathology symptoms), and each item ranges from 1 to 7. The PANSS total score is a sum of scores from all items, ranging from 30 to 210, where a higher score represents severer psychotic symptoms in patients with schizophrenia.

    Time frame: 6 weeks

Secondary outcomes

  1. Clinical Global Impression-Severity (CGI-S) score

    The Clinical Global Impression-Severity (CGI-S) score ranges from 1 to 7. A higher score represents a severer clinical impression on the patient's severity based on investigator/clinician's judgment.

    Time frame: 6 weeks

  2. The Personal and Social Performance Scale (PSP) global score

    The Personal and Social Performance Scale (PSP) contains four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. A higher domain score represents worse functional performance in each domain. The final global score is defined according to a summary instruction table converting four domain scores into a single, overall rating from 1 to 100, where a higher score represents better personal and social function.

    Time frame: 6 weeks

  3. Positive and Negative Syndrome Scale (PANSS) positive scale score

    The Positive and Negative Syndrome Scale (PANSS) positive scale includes 7 items, assessing positive symptoms in schizophrenia such as delusion, hallucinatory or excitement, and each item ranges from 1 to 7. The positive scale score is a sum of scores from the 7 items, ranging from 7 to 49, where a higher score represents severer schizophrenia positive symptoms.

    Time frame: 6 weeks

  4. Positive and Negative Syndrome Scale (PANSS) negative scale score

    The Positive and Negative Syndrome Scale (PANSS) negative scale includes 7 items, assessing negative symptoms in schizophrenia such as blunted affect or emotional withdrawal, and each item ranges from 1 to 7. The negative scale score is a sum of scores from the 7 items, ranging from 7 to 49, where a higher score represents severer schizophrenia negative symptoms.

    Time frame: 6 weeks

  5. Clinical Global Impression-Improvement (CGI-I) score

    The Clinical Global Impression-Improvement (CGI-I) score ranges from 1 to 7. A higher score represents a poorer clinical impression on the patient's improvement based on investigator/clinician's judgment.

    Time frame: 6 weeks

  6. Response rate

    defined as reduction of ≥ 30% from baseline in PANSS Total Score OR CGI-I score of 1 \[very much improved\] or 2 \[much improved\]) at Week 6

    Time frame: 6 weeks

07

Study locations

1 site
  • No.15 Yanyin Road, Yanta District
    Xi'an, Shanxi 710061, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Aug 2021, 20 months.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 20 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 14, 2019
StartActual
Nov 27, 2019
Primary completionActual
Aug 6, 2021
CompletionActual
Sep 6, 2021
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03874494
Responsible party
Sponsor
First posted
Mar 14, 2019
Start date
Nov 27, 2019
Primary completion
Aug 6, 2021
Completion
Sep 6, 2021
Last update
Apr 18, 2025

Study contacts

Hongyan Zhang, PhD
principal investigator · Peking University Sixth Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion